Experts Attempt to Demystify Paxlovid Prescribing
(MedPage Today) -- Nirmatrelvir/ritonavir (Paxlovid) may interact with a number of medications, but that does not mean doctors should shy away from prescribing it, Infectious Diseases Society of America (IDSA) experts said during a press call on... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 20, 2022 Category: American Health Source Type: news

Caution Urged With Paxlovid in Transplant Patients
(MedPage Today) -- Solid organ transplant recipients prescribed nirmatrelvir/ritonavir (Paxlovid) for COVID-19 should have their immunosuppressive drugs held and medication concentrations checked, and should undergo drug monitoring every 2 weeks... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - May 13, 2022 Category: Infectious Diseases Source Type: news

What Paxlovid Rebound Could Mean for Patients
(MedPage Today) -- In this video, Michael Mina, MD, PhD, formerly an epidemiologist at Harvard and now chief science officer of eMed, discusses the cause of viral rebound with ritonavir/nirmatrelvir (Paxlovid), what it could mean for the evolution... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 13, 2022 Category: American Health Source Type: news

Here ’s What You Need to Know About Paxlovid
Prescriptions for Pfizer’s COVID-19 antiviral medication Paxlovid—the first such pill to be authorized by the U.S. Food and Drug Administration (FDA)—have increased tenfold in the past two months. Between late February and April 22, the number of patients using Paxlovid jumped from 8,000 to 80,000, according to Pfizer CEO Albert Bourla; the drug is now available at some 33,000 locations, such as pharmacies and outpatient clinics, across the country. On April 26, the White House announced it would step up its efforts to encourage more doctors to prescribe the antiviral medication. As part of this, the Bide...
Source: TIME: Health - May 9, 2022 Category: Consumer Health News Authors: Kyla Mandel Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

Case Series Hints at Possible Paxlovid Role in Long COVID
(MedPage Today) -- Nirmatrelvir/ritonavir (Paxlovid) appeared to alleviate long COVID symptoms in two patients but was unable to prevent the development of long COVID in another, a small case series found. Two of the individuals took nirmatrelvir... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 6, 2022 Category: American Health Source Type: news

What Do We Know About Paxlovid Rebound?
(MedPage Today) -- It's not yet clear exactly how often it happens, but doctors are confident they're observing relapses after 5-day courses of nirmatrelvir/ritonavir (Paxlovid) for COVID-19. Paul Sax, MD, clinical director of infectious diseases... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 6, 2022 Category: American Health Source Type: news

NIH Probes Paxlovid Relapses; Pandemic of Unvaxxed No More? Musk Disses Wellbutrin
(MedPage Today) -- Note that some links may require registration or subscription. An NIH official said it is "urgent" to find out why some patients have experienced viral rebound after taking nirmatrelvir/ritonavir (Paxlovid) for COVID-19. (Bloomberg... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 2, 2022 Category: American Health Source Type: news

Pfizer shares top-line results from Phase 2/3 EPIC-PEP study of PAXLOVID ™ for post-exposure prophylactic use
Pfizer Inc. (NYSE: PFE) shared top-line results from the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) study evaluating PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for post-exposure prophylactic use. In this trial, compared to placebo, Pfizer observed risk reductions of 32% and 37% in adults who received PAXLOVID for five and ten days, respectively, to prevent infection. (Source: World Pharma News)
Source: World Pharma News - May 2, 2022 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

ICMR task force meets to discuss inclusion of Pfizer ’s Paxlovid for Covid treatment
Pfizer ’s Paxlovid contains Nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and Ritonavir, which slows down Nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations. It’s administered as three tablets—two of Nirmatrelv ir and one of Ritonavir—taken together orally twice daily for five days (30 tablets in total). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 27, 2022 Category: Pharmaceuticals Source Type: news

Biden Administration Beefs Up Access to COVID Antiviral Pills
(MedPage Today) -- The Biden administration plans to make Pfizer's antiviral COVID pill nirmatrelvir-ritonavir (Paxlovid) more widely available at pharmacies and expand its so-called test-to-treat program, senior administration officials told reporters... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - April 26, 2022 Category: Infectious Diseases Source Type: news

WHO updates living guideline on therapeutics and Covid-19, WHO (updated 22nd April 2022)
Update includes strong recommendation for use of nirmatrelvir/ritonavir in those with non-severe illness at highest hospitalisation risk; a conditional recommendation (CR) against use in low risk patients; and CR for use of remdesivir in those at highest risk of hospitalisation. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 25, 2022 Category: Consumer Health News Source Type: news

Philly Yanks Mask Mandate; No Vax for Tots Until June? Man Has COVID for 505 Days
(MedPage Today) -- Note that some links may require registration or subscription. The World Health Organization strongly recommended use of Pfizer's oral antiviral treatment nirmatrelvir/ritonavir (Paxlovid) for high-risk patients in a new statement... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 22, 2022 Category: American Health Source Type: news

Africa: WHO Recommends Highly Successful Covid-19 Therapy and Calls for Wide Geographical Distribution and Transparency From Originator
[WHO] Today, WHO made a strong recommendation for nirmatrelvir and ritonavir, sold under the name Paxlovid, for mild and moderate COVID-19 patients at highest risk of hospital admission, calling it the best therapeutic choice for high-risk patients to date. However, availability, lack of price transparency in bilateral deals made by the producer, and the need for prompt and accurate testing before administering it, are turning this life-saving medicine into a major challenge for low- and middle-income countries. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - April 22, 2022 Category: African Health Source Type: news

World Health Organization 'strongly recommends' Pfizer's COVID-19 pill
US pharma giant Pfizer's combination of nirmatrelvir and ritonavir was the "superior choice" of treatment for unvaccinated, elderly or immunocompromised people with Covid, the WHO's experts said in the BMJ medical journal. (Source: The Economic Times)
Source: The Economic Times - April 22, 2022 Category: Consumer Health News Source Type: news

COVID-19 rapid guideline: managing COVID-19 [NG191],NICE (updated 13th April 2022)
This guideline covers the management of COVID-19 for children, young people and adults in all care settings. It brings together our existing recommendations on managing COVID-19, and new recommendations on therapeutics, so that healthcare staff and those planning and delivering services can find and use them more easily. We are continually monitoring the evidence and updating the guideline as new information emerges. 13 April 2022 We added a new recommendation on nirmatrelvir and ritonavir (Paxlovid) for people at high risk of progression to severe COVID-19. 30 March 2022 We updated existing recommendations on casiriv...
Source: Current Awareness Service for Health (CASH) - April 14, 2022 Category: Consumer Health News Source Type: news